Thymic carcinoma pathophysiology

Jump to navigation Jump to search

Thymic Carcinoma Microchapters

Home

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Thymic carcinoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

Staging

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

Echocardiograph and Ultrasound

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Future or Investigational Therapies

Case Studies

Case #1

Thymic carcinoma pathophysiology On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Google Images

American Roentgen Ray Society Images of Thymic carcinoma pathophysiology

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Thymic carcinoma pathophysiology

CDC on Thymic carcinoma pathophysiology

Thymic carcinoma pathophysiology in the news

Blogs on Thymic carcinoma pathophysiology

Directions to Hospitals Treating Type page name here

Risk calculators and risk factors for Thymic carcinoma pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Marjan Khan M.B.B.S.[2]

Overview

The thymic carcinoma is a tumor of the thymic epithelium, but it is associated with a lack of immature lymphocytes and often presents with a more invasive or metastatic disease.[1] The pathophysiology of thymic carcinoma depends on the histological subtype. On microscopic histopathological analysis, thymic carcinoma is divided into squamous cell carcinoma, basaloid carcinoma, mucoepidermoid carcinoma, lymphoepithelioma-like carcinoma, sarcomatoid carcinoma (carcinosarcoma), clear cell carcinoma, papillary adenocarcinoma, carcinoma with t(15;19) translocation, neuroendrocrine carcinomas, undifferentiated carcinoma, and combined thymic epithelial tumors.[2] Thymic carcinoma has not been reported in association with myasthenia gravis, in contrast with thymoma[3]

Pathophysiology

Genetics

  • Development of thymic carcinoma is the result of multiple genetic mutations.[3]
  • Genetic mutations involved in the pathogenesis of thymic carcinoma include:
  • Gain of chromosome 1q, 17q, and 18
  • Deletion of chromosome 3p, 6, 13q, 16q, and 17p

Associated Conditions

  • Paraneoplasic syndromes has been reported among patients with thymic cancer (neuroendocrine subtype), however the syndrome is not as common as with thymoma patients.

Microscopic Pathology

On microscopic histopathological analysis, characteristic findings of thymic carcinoma are:

  • Cytologically malignant - variable morphology
  • +/-Squamous differentiation

Immunohistochemistry

  • CD5 +ve (90% of cases)
  • CD117 +ve (87% of cases)
  • CD7 +ve
  • TTF-1 -ve

References

  1. 1.0 1.1 Thomas CR, Wright CD, Loehrer PJ (1999). "Thymoma: state of the art". Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 17 (7): 2280–9. PMID 10561285. Retrieved 2012-01-18. Unknown parameter |month= ignored (help)
  2. Suster, S.; Rosai, J. (1991). "Thymic carcinoma. A clinicopathologic study of 60 cases". Cancer. 67 (4): 1025–32. PMID 1991250. Unknown parameter |month= ignored (help)
  3. 3.0 3.1 Harris, C.C (2004), Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart (PDF), Lyon: IARC, retrieved 01/03/2016 Check date values in: |accessdate= (help)